Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer

Breast Cancer Clinical Trial

Official title:

An Open-label, Randomised, Phase II Study of Docetaxel in Combination With a Dietary Phytonutrient in First or Second Line Treatment for Patients With HER2 Negative Locally Advanced or Metastatic Breast Cancer, or Loco-regional Recurrence Not Amenable to Treatment by Surgery or Radiotherapy.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00852332
• Other study ID #: CDR0000635901
• Secondary ID: JEANP-CURRYTAXIN
• Status: Terminated
• Phase: Phase 2
• Start date: August 2009
• Est. completion date: November 2017

Study information

• Verified date: July 2018
• Source: Centre Jean Perrin
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Dietary supplements, such as phytochemicals, may stop or delay the development of breast cancer. It is not yet known whether giving docetaxel together with a phytochemical is more effective than giving docetaxel alone in treating patients with breast cancer.

PURPOSE: This randomized phase II trial is studying how well giving docetaxel together with a phytochemical works compared with giving docetaxel alone as first- or second-line therapy in treating patients with breast cancer.

Description:

OBJECTIVES:

Primary

• To compare the response rate in HER2-negative patients with locally advanced or metastatic breast cancer or locoregional breast cancer recurrence treated with docetaxel and a dietary phytochemical vs docetaxel alone.

Secondary

• To compare the overall clinical benefit rate (i.e., objective response plus stable disease) in patients treated with these regimens.

• To compare time to progression in patients treated with these regimens.

• To compare overall survival of patients treated with these regimens.

• To assess biomarkers of response in blood samples from patients treated with these regimens.

OUTLINE: This is a multicenter study. Patients are stratified according to recruitment center and line of chemotherapy (first vs second line of docetaxel). Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive docetaxel IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

• Arm II: Patients receive docetaxel as in arm I. Patients also receive an oral dietary phytochemical twice on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed periodically.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 42
• Est. completion date: November 2017
• Est. primary completion date: November 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 120 Years

Eligibility

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed adenocarcinoma of the breast, meeting 1 of the following criteria:

• Locally advanced disease

• Documented metastatic disease without overexpression of Her2/neu

• Must have received prior anthracycline-containing regimen as neoadjuvant, adjuvant, or first-line chemotherapy for metastatic breast cancer

• Loco-regional recurrence not amenable to treatment by surgery or radiotherapy

• At least one measurable lesion according to RECIST criteria

• No bone lesion only disease

• Must be a candidate for taxane-based chemotherapy

• HER2-negative disease

• No symptomatic brain metastases

• Hormone receptor status not specified

PATIENT CHARACTERISTICS:

• Menopausal status not specified

• WHO performance status 0-2

• Life expectancy = 3 months

• ANC = 2,000/mm³

• Platelet count = 100,000/mm³

• Hemoglobin = 10 g/dL

• Serum creatinine < 140 µmol/L OR creatinine clearance > 60 mL/min

• Total bilirubin = upper limit of normal (ULN)

• AST and ALT = 1.5 times ULN

• Alkaline phosphatase = 2.5 times ULN

• Not pregnant or nursing

• Fertile patients must use effective contraception

• No history of significant neurologic (i.e., peripheral neuropathy = grade 2) or psychiatric disorders, including psychotic disorders, dementia, or seizures that would prohibit the understanding, observance, and giving of informed consent

• No other prior or concomitant malignancies except adequately treated carcinoma in situ of the cervix uteri, basal cell or squamous cell carcinoma of the skin, or other cancer curatively treated with surgery and/or radiotherapy

• No concurrent severe and/or uncontrolled co-morbid medical condition

• No medically unstable patients

• No uncontrolled infection

• No autoimmune disease and/or chronic active inflammation

• No psychological, familial, social, or geographical reasons that would make clinical follow-up impossible

• No malabsorption syndrome or disease significantly affecting gastrointestinal function

• No dysphagia = grade 2

• No history of hypersensitivity to taxanes or known excipients, including polysorbate 80

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No prior major resection of the stomach or proximal small bowel

• Prior hormonal therapy as adjuvant treatment and/or treatment of metastatic disease allowed provided that the patient has progressive disease at study entry

• Hormonal treatment must be discontinued prior to study entry

• No more than 1 prior chemotherapy regimen for metastatic disease

• More than 30 days since prior investigational drug

• More than 3 weeks since prior NSAIDs or COX_2 inhibitors

• No other concurrent anticancer therapy

• No other concurrent dietary phytonutrients

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Dietary Supplement:
• Curcumin

Drug:
• Taxotere

Locations

Country	Name	City	State
France	Centre Jean Perrin	Clermont-Ferrand

Sponsors (1)

Lead Sponsor	Collaborator
Centre Jean Perrin

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response rate as assessed by RECIST criteria		From the date of randomization until the end of the treatment, assessed up to 21 weeks
Secondary	Overall clinical benefit rate as assessed by RECIST criteria		From the date of randomization until the end of the treatment, assessed up to 21 weeks
Secondary	Time to progression as assessed by RECIST criteria		From date of randomization until the date of first documented progression or date of death from any cause, assessed up to 21 weeks
Secondary	Overall survival as assessed by RECIST criteria	Evaluate overall survival (between inclusion and death whatever the cause)	From the date of randomization until the date of death from any cause
Secondary	Safety as assessed by NCI CTCAE v3.0		From the date of randomization until the end of the treatment, assessed up to 21 weeks